当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

インデックス付き
  • 索引コペルニクス
  • Google スカラー
  • シェルパ・ロミオ
  • Genamics JournalSeek
  • セーフティライト付き
  • レフシーク
  • ハムダード大学
  • エブスコ アリゾナ州
  • OCLC-WorldCat
  • パブロン
  • ジュネーブ医学教育研究財団
  • ユーロパブ
  • ICMJE
このページをシェアする

抽象的な

Magnitude of the Difference between Fasting and Non-fasting Triglycerides, and Its Dependent Factors

Shuman Yang, Min Liu and Tianying Wu

Background: It is largely unknown about the magnitude of the difference between fasting and non-fasting triglycerides, and whether this difference is dependent on certain potential cardiovascular disease (CVD) risk factors.

Methods: We conducted a cross-sectional study of 8,073 participants from the National Health and Nutrition Examination Survey, 2005-2010. Fasting status was classified into two groups: fasting (≥8 hours) and non-fasting status (<8 hours). The difference between fasting and non-fasting triglycerides its dependent CVD risk factors were estimated with linear regression model.

Results: Overall, fasting participants had lower triglycerides than non-fasting participants after adjusting for covariates (difference=4.22 mg/dL; P=0.049). Triglycerides levels at fasting status was interacted with hypertension (P=0.05), antihyperlipidemic agent use (P=0.07) and LDL cholesterol (P=0.04). In the separate analyses of the participants with and without hypertension, antihyperlipidemic agent use, or with high and low levels of LDL cholesterol, fasting triglycerides were much lower than non-fasting triglycerides only in participants with hypertension (difference=14.24 mg/dL; P=0.03), antihyperlipidemic agent use (difference=14.10 mg/dL; P=0.02), or LDL cholesterol <130 mg/dL (difference=6.46 mg/dL; P=0.02).

Conclusions: The difference between fasting and non-fasting triglycerides was 4 mg/dL in the overall samples, and factors that determine the magnitude of differences were hypertension status, antihyperlipidemic agent use and LDL cholesterol levels. These findings may help us to use fasting and non-fasting triglycerides properly to assess the risk of CVDs.